CA3093084A1 - Imidazodiazepinediones and methods of use thereof - Google Patents
Imidazodiazepinediones and methods of use thereof Download PDFInfo
- Publication number
- CA3093084A1 CA3093084A1 CA3093084A CA3093084A CA3093084A1 CA 3093084 A1 CA3093084 A1 CA 3093084A1 CA 3093084 A CA3093084 A CA 3093084A CA 3093084 A CA3093084 A CA 3093084A CA 3093084 A1 CA3093084 A1 CA 3093084A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- optionally substituted
- alkyl
- methyl
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862638448P | 2018-03-05 | 2018-03-05 | |
| US62/638,448 | 2018-03-05 | ||
| PCT/US2019/020732 WO2019173327A1 (en) | 2018-03-05 | 2019-03-05 | Imidazodiazepinediones and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3093084A1 true CA3093084A1 (en) | 2019-09-12 |
Family
ID=67847465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3093084A Pending CA3093084A1 (en) | 2018-03-05 | 2019-03-05 | Imidazodiazepinediones and methods of use thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11623930B2 (https=) |
| EP (1) | EP3761989A4 (https=) |
| JP (2) | JP7408557B2 (https=) |
| CN (2) | CN118908961A (https=) |
| AU (2) | AU2019231208B2 (https=) |
| CA (1) | CA3093084A1 (https=) |
| WO (1) | WO2019173327A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3093084A1 (en) | 2018-03-05 | 2019-09-12 | Goldfinch Bio, Inc. | Imidazodiazepinediones and methods of use thereof |
| JP2022551580A (ja) * | 2019-10-04 | 2022-12-12 | ゴールドフィンチ バイオ，インク． | 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置 |
| CN115927202A (zh) * | 2023-01-10 | 2023-04-07 | 北京爱思益普生物科技股份有限公司 | 一种trpc5突变细胞株及其构建方法和应用 |
| WO2024153028A1 (zh) * | 2023-01-20 | 2024-07-25 | 深圳晶蛋生物医药科技有限公司 | 大环类化合物、其药物组合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994020460A1 (en) * | 1993-03-11 | 1994-09-15 | Smithkline Beecham Corporation | Chemical compounds |
| WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| TW201444844A (zh) * | 2013-03-14 | 2014-12-01 | Hydra Biosciences Inc | 經取代之黃嘌呤及使用其之方法 |
| CN107082782B (zh) | 2013-03-15 | 2020-03-20 | 海德拉生物科学有限责任公司 | 取代的黄嘌呤及其使用方法 |
| JP6667092B2 (ja) | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体 |
| DK3652176T3 (da) | 2017-07-11 | 2022-01-17 | Boehringer Ingelheim Int | Substituerede xanthinderivater |
| CA3093084A1 (en) | 2018-03-05 | 2019-09-12 | Goldfinch Bio, Inc. | Imidazodiazepinediones and methods of use thereof |
| EP3917940A1 (en) * | 2019-01-30 | 2021-12-08 | Rothamsted Research Ltd | Cylodimer of dehydrosalicortin and derivatives thereof isolated from plant of the genus salix for use in cancer therapy |
-
2019
- 2019-03-05 CA CA3093084A patent/CA3093084A1/en active Pending
- 2019-03-05 EP EP19763337.3A patent/EP3761989A4/en active Pending
- 2019-03-05 CN CN202410783264.2A patent/CN118908961A/zh active Pending
- 2019-03-05 US US16/977,945 patent/US11623930B2/en active Active
- 2019-03-05 CN CN201980030356.0A patent/CN112351781B/zh active Active
- 2019-03-05 WO PCT/US2019/020732 patent/WO2019173327A1/en not_active Ceased
- 2019-03-05 JP JP2020543957A patent/JP7408557B2/ja active Active
- 2019-03-05 AU AU2019231208A patent/AU2019231208B2/en active Active
-
2023
- 2023-02-01 US US18/104,610 patent/US12466834B2/en active Active
- 2023-12-19 JP JP2023214175A patent/JP7809096B2/ja active Active
-
2025
- 2025-04-17 AU AU2025202716A patent/AU2025202716A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024037971A (ja) | 2024-03-19 |
| US20210087200A1 (en) | 2021-03-25 |
| US20230365575A1 (en) | 2023-11-16 |
| AU2019231208B2 (en) | 2025-01-23 |
| JP7408557B2 (ja) | 2024-01-05 |
| EP3761989A4 (en) | 2021-11-24 |
| US11623930B2 (en) | 2023-04-11 |
| JP7809096B2 (ja) | 2026-01-30 |
| AU2025202716A1 (en) | 2025-05-08 |
| CN112351781A (zh) | 2021-02-09 |
| US12466834B2 (en) | 2025-11-11 |
| JP2021516225A (ja) | 2021-07-01 |
| WO2019173327A1 (en) | 2019-09-12 |
| AU2019231208A1 (en) | 2020-09-17 |
| CN118908961A (zh) | 2024-11-08 |
| CN112351781B (zh) | 2024-07-02 |
| EP3761989A1 (en) | 2021-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3852533B1 (en) | Pyridazinones and methods of use thereof | |
| JP7809096B2 (ja) | イミダゾジアゼピンジオン及びその使用方法 | |
| JP7571039B2 (ja) | ピリダジノン及びその使用法 | |
| KR20210005222A (ko) | Rip1 억제 화합물 및 이를 제조하고 사용하는 방법 | |
| CA3208490A1 (en) | Analogs for the treatment of disease | |
| RU2687490C2 (ru) | Ppar-поддерживающие соединения для лечения метаболических заболеваний | |
| TWI617553B (zh) | 吖丁啶基氧苯基吡咯啶化合物 | |
| WO2019028308A1 (en) | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES AND METHODS OF USE | |
| HK40115225A (en) | Pyridazinones and methods of use thereof | |
| HK40056020B (en) | Pyridazinones and methods of use thereof | |
| HK40056020A (en) | Pyridazinones and methods of use thereof | |
| EA048445B1 (ru) | Пиридазиноны и способы их применения | |
| CA3155338A1 (en) | Xanthine cb1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240305 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20241127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241127 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250130 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250130 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250130 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250328 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250424 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250822 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250909 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251029 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251029 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260203 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260408 |